CL2011002206A1 - Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. - Google Patents

Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.

Info

Publication number
CL2011002206A1
CL2011002206A1 CL2011002206A CL2011002206A CL2011002206A1 CL 2011002206 A1 CL2011002206 A1 CL 2011002206A1 CL 2011002206 A CL2011002206 A CL 2011002206A CL 2011002206 A CL2011002206 A CL 2011002206A CL 2011002206 A1 CL2011002206 A1 CL 2011002206A1
Authority
CL
Chile
Prior art keywords
alzheimer
pharmaceutical composition
cns
modulators
activator
Prior art date
Application number
CL2011002206A
Other languages
English (en)
Spanish (es)
Inventor
Tetsuya Tsukamoto
Takeshi Wakabayashi
Taiichi Ohra
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2011002206A1 publication Critical patent/CL2011002206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2011002206A 2009-03-10 2011-09-08 Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras. CL2011002206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009056719 2009-03-10

Publications (1)

Publication Number Publication Date
CL2011002206A1 true CL2011002206A1 (es) 2012-02-03

Family

ID=42224778

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002206A CL2011002206A1 (es) 2009-03-10 2011-09-08 Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.

Country Status (37)

Country Link
US (4) US8957069B2 (enExample)
EP (2) EP2406243B1 (enExample)
JP (2) JP5746631B2 (enExample)
KR (1) KR20110128913A (enExample)
CN (2) CN103965147B (enExample)
AR (1) AR076098A1 (enExample)
AU (1) AU2010221979A1 (enExample)
BR (1) BRPI1009252A2 (enExample)
CA (1) CA2754904A1 (enExample)
CL (1) CL2011002206A1 (enExample)
CO (1) CO6420340A2 (enExample)
CR (1) CR20110474A (enExample)
CY (1) CY1115469T1 (enExample)
DK (1) DK2406243T3 (enExample)
DO (1) DOP2011000281A (enExample)
EA (1) EA201171020A1 (enExample)
EC (1) ECSP11011318A (enExample)
ES (1) ES2487616T3 (enExample)
HK (1) HK1202293A1 (enExample)
HR (1) HRP20140687T1 (enExample)
IL (1) IL214667A0 (enExample)
MA (1) MA33159B1 (enExample)
MX (1) MX2011009394A (enExample)
NZ (1) NZ594847A (enExample)
PE (1) PE20120357A1 (enExample)
PL (1) PL2406243T3 (enExample)
PT (1) PT2406243E (enExample)
RS (1) RS53416B (enExample)
SG (1) SG173757A1 (enExample)
SI (1) SI2406243T1 (enExample)
SM (1) SMT201500027B (enExample)
TN (1) TN2011000422A1 (enExample)
TW (1) TWI477497B (enExample)
UA (1) UA107657C2 (enExample)
UY (1) UY32481A (enExample)
WO (1) WO2010104194A1 (enExample)
ZA (1) ZA201106045B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110128913A (ko) * 2009-03-10 2011-11-30 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체
JPWO2011062194A1 (ja) 2009-11-18 2013-04-04 武田薬品工業株式会社 アミノピリジン誘導体
ES2861300T3 (es) 2012-02-20 2021-10-06 Basf Se Potenciación de la actividad antimicrobiana de biocidas con polímeros
US9816233B2 (en) * 2012-09-28 2017-11-14 Kimberly-Clark Worldwide, Inc. Hybrid fiber compositions and uses in containerboard packaging
US9908680B2 (en) 2012-09-28 2018-03-06 Kimberly-Clark Worldwide, Inc. Tree-free fiber compositions and uses in containerboard packaging
WO2014053409A1 (en) * 2012-10-01 2014-04-10 F. Hoffmann-La Roche Ag Benzimidazol.es as cns active agents
WO2015036412A1 (en) * 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Indol-carboxamide derivatives
SG11201912770SA (en) 2017-06-23 2020-01-30 Kyowa Kirin Co Ltd a, ß-UNSATURATED AMIDE COMPOUND
CN109580790A (zh) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 一种液相色谱法分离测定西洛多辛及其光学异构体的方法
CN108530405A (zh) * 2018-05-08 2018-09-14 南京晓庄学院 非金属路易斯酸催化烯烃分子内加成c-o键合成苯并呋喃衍生物的方法
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
TWI894229B (zh) * 2020-03-16 2025-08-21 瑞士商諾華公司 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
CN111362965B (zh) * 2020-04-27 2022-05-03 梯尔希（南京）药物研发有限公司 一种莫西菌素杂质的制备方法
CN113219085B (zh) * 2021-03-31 2022-05-13 河北国龙制药有限公司 一种2,3-二甲基溴苯有关物质的检测方法
CN113214205B (zh) * 2021-04-09 2022-06-10 南方海洋科学与工程广东省实验室(湛江) 一种色原酮衍生物的制备方法
CN115260136B (zh) * 2022-08-09 2023-08-15 嘉兴学院 一种苯酞类化合物及其制备方法
CN115724721A (zh) * 2022-12-19 2023-03-03 山东京博石油化工有限公司 一种2-取代基-4-溴苯酚的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69898A0 (en) 1982-10-08 1984-01-31 Ciba Geigy Ag Furans
JPH04149546A (ja) 1990-10-15 1992-05-22 Konica Corp 有機着色物質の光褪色防止方法
TW199152B (enExample) 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
JP4149546B2 (ja) 1996-12-24 2008-09-10 株式会社東芝 半導体装置の製造方法
US7008950B1 (en) 1997-06-05 2006-03-07 Takeda Chemical Industries, Ltd. Benzofurans as suppressors of neurodegeneration
JPH1149765A (ja) * 1997-06-05 1999-02-23 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JP2003524571A (ja) 1997-07-25 2003-08-19 ハー・ルンドベック・アクチエゼルスカベット インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
PT1136477E (pt) 1998-12-04 2004-08-31 Takeda Chemical Industries Ltd Derivados do benzofurano processo para a sua preparacao e suas utilizacoes
DE19932314A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
CA2378878A1 (en) 1999-07-29 2001-02-08 Jeffrey Thomas Mullaney Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
DE19958496A1 (de) 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
US20040094431A1 (en) * 2000-06-12 2004-05-20 Howard A. Fromson Brush graining
AU2001292350A1 (en) 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
US7208495B2 (en) 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
KR101011657B1 (ko) * 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
ES2292949T3 (es) 2002-04-02 2008-03-16 Janssen Pharmaceutica Nv Derivados de aminoisoxazolina sustituidos y su uso anti-represivos.
EP1350769A1 (de) * 2002-04-04 2003-10-08 Bystronic Maschinen AG Vorrichtung und Verfahren zum Teilen von vertikalen Glasplatten
NZ538713A (en) 2002-08-12 2007-01-26 Takeda Chemical Industries Ltd Fused benzene derivative and use
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
JP2007500221A (ja) 2003-05-20 2007-01-11 ジェネンテック・インコーポレーテッド 第ＶＩＩａ因子のベンゾフラン阻害剤
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
US7465815B2 (en) 2003-06-26 2008-12-16 Takeda Pharmaceutical Company Limited Cannabinoid receptor modulator
JP3678733B2 (ja) * 2003-10-03 2005-08-03 株式会社エヌ・ティ・ティ・ドコモ 携帯通信端末及び位置情報提供方法
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050095401A1 (en) * 2003-11-04 2005-05-05 Fuji Photo Film Co., Ltd. Image recording material and depression-and-protrusion forming method
EP1730145A1 (en) 2004-03-22 2006-12-13 Boehringer Ingelheim Pharmaceuticals Inc. Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics
ATE461932T1 (de) * 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DE102004063797A1 (de) * 2004-12-30 2006-07-13 Schwarz Pharma Ag Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP5182088B2 (ja) 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
HRP20090395T1 (hr) * 2006-04-19 2009-08-31 Boehringer Ingelheim International Gmbh Dihidrotienpirimidini za liječenje upalnih bolesti
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
HU230729B1 (hu) 2007-05-30 2017-12-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Új, szelektív 5HT7-receptorgátló benzofurán-származékok és eljárás előállításukra
US8382180B2 (en) * 2007-10-31 2013-02-26 Applied Material, Inc. Advanced FI blade for high temperature extraction
KR101616140B1 (ko) 2008-03-05 2016-04-27 다케다 야쿠힌 고교 가부시키가이샤 복소환 화합물
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
KR20110128913A (ko) * 2009-03-10 2011-11-30 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체

Also Published As

Publication number Publication date
US20120232095A1 (en) 2012-09-13
MX2011009394A (es) 2011-10-11
IL214667A0 (en) 2011-09-27
DOP2011000281A (es) 2011-10-31
UY32481A (es) 2010-09-30
US8957069B2 (en) 2015-02-17
US8288390B2 (en) 2012-10-16
UA107657C2 (uk) 2015-02-10
AU2010221979A1 (en) 2011-09-15
ZA201106045B (en) 2012-10-31
PE20120357A1 (es) 2012-05-03
KR20110128913A (ko) 2011-11-30
CN102421767B (zh) 2014-06-18
EP2406243A1 (en) 2012-01-18
CY1115469T1 (el) 2017-01-04
AR076098A1 (es) 2011-05-18
HK1202293A1 (en) 2015-09-25
EP2781513A1 (en) 2014-09-24
SMT201500027B (it) 2015-05-05
JP2012520238A (ja) 2012-09-06
JP5841651B2 (ja) 2016-01-13
US20120046277A1 (en) 2012-02-23
SG173757A1 (en) 2011-09-29
DK2406243T3 (da) 2014-07-21
MA33159B1 (fr) 2012-03-01
SI2406243T1 (sl) 2014-08-29
ES2487616T3 (es) 2014-08-22
EP2406243B1 (en) 2014-05-07
BRPI1009252A2 (pt) 2016-03-15
PL2406243T3 (pl) 2014-10-31
HRP20140687T1 (hr) 2014-10-24
US20100234357A1 (en) 2010-09-16
CN103965147A (zh) 2014-08-06
PT2406243E (pt) 2014-07-11
CO6420340A2 (es) 2012-04-16
RS53416B (sr) 2014-12-31
JP5746631B2 (ja) 2015-07-08
TN2011000422A1 (en) 2013-03-27
CN103965147B (zh) 2016-08-24
TWI477497B (zh) 2015-03-21
JP2015044848A (ja) 2015-03-12
WO2010104194A1 (en) 2010-09-16
NZ594847A (en) 2013-10-25
US20120232096A1 (en) 2012-09-13
TW201036960A (en) 2010-10-16
CN102421767A (zh) 2012-04-18
CA2754904A1 (en) 2010-09-16
ECSP11011318A (es) 2011-10-31
CR20110474A (es) 2011-12-01
EA201171020A1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
ECSP088402A (es) Compuestos y composiciones que contienen diarilamina, y su utilización como moduladores de los receptores c-kit
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2008001374A1 (es) Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia.
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR047759A1 (es) Derivados de fenil - piperazina como moduladores de receptores muscarnicos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
HN2010002774A (es) DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA
CL2013002394A1 (es) Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros.